Oral supplementation of Pediococcus pentosaceus SMM847 ameliorates hyperuricemia in rats and alcohol-induced injury in mice

This study presents the probiotic strain Pediococcus pentosaceus SMM847 as a promising therapeutic agent for two clinically significant conditions: hyperuricemia and acute alcohol intoxication. The strain mediates uric acid reduction through modulation of purine catabolism pathways. It is particularly noteworthy that SMM847 exhibits ethanol-catabolizing activity, attenuates alcohol-elicited systemic metabolic dysregulation, and exerts hepatoprotection without intrinsic toxicity. The ability of this single bacterial entity to simultaneously target dual pathological pathways-uric acid metabolism and alcohol-induced metabolic disruption-offers a novel and translatable approach for the development of functional foods or pharmaceutical interventions aimed at promoting integrated metabolic and hepatic health.